← Back to Search

Optical Imaging Device

PS-OCT Eye Scan for Retinal Imaging

N/A
Waitlist Available
Led By Benjamin Vakoc, Ph.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects with clear enough cornea or clear enough media to permit imaging
Be older than 18 years old
Must not have
Subjects who have occludable narrow angles (without a patent peripheral iridotomy) or any other ocular or systemic pathology, which precludes safe dilation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of imaging
Awards & highlights
No Placebo-Only Group

Summary

This trial assesses a new eye scan's ability to see retinal detail.

Who is the study for?
This trial is for men and women aged 18-85 who are generally healthy with no significant eye diseases, except mild cataracts. Participants should have a clear cornea or media allowing for imaging and a refractive error within -5.00 to +5.00 spherical units.
What is being tested?
The study is testing the effectiveness of a new retinal imaging system called Polarization-Sensitive Optical Coherence Tomography (PS-OCT). It aims to capture high-quality images of the retina's birefringence in healthy subjects.
What are the potential side effects?
Since this trial involves non-invasive imaging technology, there are minimal expected side effects, primarily related to light exposure during retinal scanning which could include temporary discomfort or visual disturbances.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My eyes are clear enough for imaging tests.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have eye conditions that prevent safe eye dilation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at time of imaging
This trial's timeline: 3 weeks for screening, Varies for treatment, and at time of imaging for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Average nerve fiber layer (NFL) birefringence

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Control: HealthyExperimental Treatment1 Intervention
Polarization Sensitive Optical Coherence Tomography (PS-OCT) Imaging will be used to look at the nerve fiber layer (NFL) in the healthy retina.

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,023 Previous Clinical Trials
13,317,929 Total Patients Enrolled
Massachusetts Eye and Ear InfirmaryOTHER
109 Previous Clinical Trials
12,661 Total Patients Enrolled
Benjamin Vakoc, Ph.D.Principal InvestigatorMassachusetts General Hospital

Media Library

Polarization-Sensitive OFDI (Optical Imaging Device) Clinical Trial Eligibility Overview. Trial Name: NCT02441777 — N/A
Healthy Subjects Research Study Groups: Control: Healthy
Healthy Subjects Clinical Trial 2023: Polarization-Sensitive OFDI Highlights & Side Effects. Trial Name: NCT02441777 — N/A
Polarization-Sensitive OFDI (Optical Imaging Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02441777 — N/A
~8 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top